Key result
Novel NT-proBNP and NPR model stratifies early mortality risk in advanced AL cardiac amyloidosis.
Why the study?
Patients with advanced light-chain cardiac amyloidosis remain at high risk of early death, and prognostic heterogeneity within Mayo 2012 stage III/IV disease limits the identification of ultra-high-risk patients during initial treatment.
Does an NT-proBNP and neutrophil-to-platelet ratio (NPR)-based model predict 3-month all-cause mortality in patients with Mayo 2012 stage III/IV light-chain cardiac amyloidosis?
Cohort (n=111)
Does an NT-proBNP and neutrophil-to-platelet ratio (NPR)-based model predict 3-month all-cause mortality in patients with Mayo 2012 stage III/IV light-chain cardiac amyloidosis?
Answers are grounded in this paper and cite their sources.
A simple prognostic model combining NT-proBNP (>5906 ng/L) and neutrophil-to-platelet ratio (>4.015) effectively stratifies 3-month early mortality risk in patients with advanced Mayo stage III/IV light-chain cardiac amyloidosis.
Patients with advanced light-chain cardiac amyloidosis (AL-CA) remain at high risk of early death despite therapeutic progress. Prognostic heterogeneity within Mayo 2012 stage III/IV disease limits identification of ultra-high-risk patients during initial treatment. We retrospectively included 111 patients with Mayo 2012 stage III/IV AL-CA and randomly divided them into training and internal validation cohorts at a 2:1 ratio. The primary endpoint was all-cause mortality within 3 months after diagnosis. In the training cohort ( n = 74), 24 patients died within 1 year, including 16 deaths within 3 months. Kaplan-Meier analysis showed a biphasic survival pattern with a sharp early decline followed by plateauing. Univariate and multivariable Cox analyses identified NT-proBNP and neutrophil-to-platelet ratio (NPR) as prognostically relevant variables for 3-month mortality. Both remained significantly associated with early mortality after additional adjustment for daratumumab-based frontline therapy. Using receiver operating characteristic (ROC)-derived cutoffs, we developed a simple model based on NT-proBNP > 5906 ng/L and NPR > 4.015. Patients meeting both criteria were classified as high-risk. The model stratified 3-month survival in the training cohort (area under the curve, AUC = 0.724, 95% CI 0.604–0.858) and retained discrimination in the validation cohort ( n = 37, AUC = 0.653, 95% CI 0.483–0.841). A complementary continuous NT-proBNP/NPR model yielded AUCs of 0.730 and 0.759 in the training and validation cohorts, respectively. Bootstrap internal validation of the continuous model using the entire cohort yielded an optimism-corrected C-index of 0.704 and an optimism-corrected calibration slope of 0.830. These findings support a simple NT-proBNP/NPR-based model for early mortality risk stratification in patients with advanced AL-CA, and may help identify ultra-high-risk patients and guide risk-adapted clinical decision-making.
No takes yet. Share an insight, caveat, or question.
Zhu et al. (2026) conducted a cohort in Advanced light-chain cardiac amyloidosis (Mayo 2012 stage III/IV) (n=111). NT-proBNP/NPR-based risk model (NT-proBNP > 5906 ng/L and neutrophil-to-platelet ratio > 4.015) vs. Low-risk classification (not meeting both cutoff criteria) was evaluated on All-cause mortality within 3 months after diagnosis (AUC 0.724 (training); AUC 0.653 (validation), 95% CI 0.604-0.858). An NT-proBNP (>5906 ng/L) and NPR model stratified 3-month mortality in advanced AL cardiac amyloidosis.
Synapse has enriched 10 related papers. Consider them for comparative context: